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Abstract
Objectives and Background—Suboptimal 25-hydroxyvitamin D [25(OH)D] is a potential 
cardiovascular risk factor. We hypothesized that low serum 25(OH)D is associated with incident 
heart failure (HF) and that the association is (a) partly mediated by traditional cardiovascular risk 
factors, (b) stronger among whites than blacks, and (c) stronger among those genetically 
predisposed to having high levels of vitamin D binding protein (DBP).
Methods—A total of 12,215 ARIC Study participants free of HF at baseline (1990-92; median 
age 56, 24% black) were followed through 2010. Total serum 25(OH)D was measured at baseline 
using LCMS. Incident HF events were identified by a hospital discharge code of ICD9-428 and 
parallel ICD codes for HF deaths.
Results—During 21 years of follow-up 1,799 incident HF events accrued. The association 
between 25(OH)D and HF varied by race (p-interaction =0.02). Among whites, risk was 2-fold 
higher for those in the lowest (≤17 ng/mL) versus highest (≥31 ng/mL) quintile of 25(OH)D. The 
association was attenuated but remained significant with covariate adjustment. In blacks there was 
no overall association. In both races, those with low 25(OH)D and the rs7041 G allele, which 
predisposes to high DBP, were at greater risk (p-interaction =0.01).
Conclusions—Low serum 25(OH)D was independently associated with incident HF among 
whites, but not among blacks. However, in both races, low 25(OH)D was associated with HF risk 
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among those genetically predisposed to high DBP. These findings provide novel insight into 
metabolic differences that may underlie racial variation in the association between 25(OH)D and 
cardiovascular risk.
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Background
Vitamin D is a fat-soluble vitamin obtained through cutaneous synthesis stimulated by sun 
exposure and through oral intake from food and supplements. Insufficient vitamin D, as 
assessed by low circulating 25-hydroxyvitamin D [25(OH)D], has recently drawn attention 
as a potential cardiovascular disease (CVD) risk factor(1,2), though this remains 
controversial(3,4). If suboptimal 25(OH)D influences CVD risk, it likely does so 
predominantly by elevating established CVD risk factors, namely hypertension(5), 
diabetes(6), and inflammation(7). Although several studies have explored associations of 
25(OH)D with risk of coronary heart disease (CHD) and stroke(1), much less is known 
about associations between 25(OH)D and incidence of heart failure (HF)(8,9).
If an association between 25(OH)D and HF exists, it is unclear whether it varies by race/
ethnicity. Relative to whites, blacks have low 25(OH)D levels but paradoxically higher bone 
density and lower fracture risk(10). Additionally, there is some suggestion that associations 
of low 25(OH)D with risk of diabetes(11), peripheral artery disease(12), stroke(13), and 
CHD(14) are stronger in whites then blacks. However, prior studies of other CVD 
phenotypes were often limited in that they were cross-sectional and/or had limited power for 
race/ethnicity-stratified analyses. Whether associations between 25(OH)D and HF differ by 
race is unknown.
Racial differences in vitamin D metabolism are believed to underlie racial/ethnic 
interactions in associations between 25(OH)D and outcomes. Foremost, recent work 
suggests that although concentrations of 25(OH)D differ between blacks and whites, levels 
of bioavailable vitamin D are similar(15). Racial variation in key vitamin D binding protein 
(DBP) SNPs (i.e. rs7041 and rs4588), which are missense mutations and together explain 
80% of the variation in DBP levels, result in blacks and whites having similar levels of 
bioavailable vitamin D despite disparate levels of 25(OH)D(15). As alternate mechanisms, 
black individuals have higher circulating concentrations of 1,25(OH)2D at a given level of 
25(OH)D(16), and vitamin D receptor gene affinity and polymorphism frequencies vary by 
race(17).
Using observational data from the prospective Atherosclerosis Risk in Communities (ARIC) 
cohort we tested the hypotheses that low serum 25(OH)D is associated with incident HF and 
that this association (a) is stronger among whites than blacks, (b) is partly mediated by 
traditional cardiovascular risk factors, and (c) is stronger among those genetically 
predisposed to having high levels of DBP. In exploratory analyses we also examined 
whether levels of the 3-epi-25(OH)D3 epimer are associated HF risk.
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Selection and Description of Participants
The ARIC study is a community-based prospective cohort which in 1987-1989 recruited a 
total of 15,792 men and women, aged 45-64 years, from four U.S. communities: Forsyth 
County, NC; Jackson, MS; suburbs of Minneapolis, MN; and Washington County, MD(18). 
Only blacks were recruited in Jackson, while participants in the other field centers reflected 
the underlying population (mostly white in MN and MD, white and black in NC). Four 
cohort re-examinations have taken place: 1990-1992 (visit 2), 1993-1995 (visit 3), 
1996-1998 (visit 4), and 2011-2013 (visit 5). Local institutional review boards approved the 
ARIC protocol, and all participants gave informed consent.
Serum 25(OH)D was measured in samples collected at ARIC visit 2 (1990-1992), which 
was attended by 14,348 participants. Thus, visit 2 is baseline for the present analysis. 
Excluded from the analysis are participants who self-identified as neither black nor white (n 
= 42), blacks from the Minnesota and Maryland centers (n = 49), those who had prevalent 
HF at visit 2 or were missing variables needed to define prevalent HF (n = 945), or with 
missing 25(OH)D data as specimens were not available for measurement (n = 1,097). For 
the primary analysis our final analytic sample included 12,215 participants. For genetic 
analyses we further excluded those who did not consent to participate in genetic research or 
had missing genetic data (n = 487; final sample = 11,728).
25(OH)D and Non-Genetic Variables
At visit 2, ARIC participants underwent interviews, fasting venipuncture, and measurement 
of blood pressure and anthropometrics. Participants brought to the visit all medications taken 
in the 2 weeks before the examination; medication names were transcribed and coded. 
Physical activity was not assessed at visit 2, so values from visit 1 were carried forward. 
Height and weight were measured, and body mass index (BMI) calculated as weight/height2. 
Sitting blood pressure was measured in triplicate with a random-zero sphygmomanometer; 
the mean of the last two measurements was analyzed. Diabetes was defined by fasting blood 
glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, a self-report of physician diagnosis, 
or current medication use for diabetes.
Participants were asked to fast for 12 hours prior to the blood draw. Plasma and serum were 
collected at visit 2 and frozen at −70°C until analyzed. Serum 25(OH)D2, 25(OH)D3, and 
the 3-epi-25(OH)D3 epimer were measured using a high sensitivity mass spectrometer (AB 
Sciex 5500) at the Advanced Research and Diagnostic Laboratory, University of Minnesota, 
Minneapolis, MN, in 2012-2013. Epimers have identical chemical structures except for a 
single site of molecular asymmetry (in this case C-3α-vs. C-3β-hydroxy); it is not presently 
known to what extent 3-epi-25(OH)D3 is physiologically active. Using split samples sent 1 
week apart, the blind duplicate coefficient of variation (CV) and Pearson correlation 
coefficients were as follows: 25(OH)D3 CV = 6.9, r = 0.97; 25(OH)D2 CV = 20.8, r = 0.98; 
3-epi-25(OH)D3 CV = 16.5, r = 0.76. Lipids were measured at the time of ARIC visit 2 
(1990-1992). Plasma total cholesterol, triglycerides, and HDL-C were measured using 
typical approaches; LDL-C was calculated. Serum magnesium was measured by the Gindler 
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and Heth procedure. In 2012-2013 high sensitivity C-reactive protein (hs-CRP) and serum 
albumin were measured on a Modular P Chemistry analyzer, serum parathyroid hormone 
(PTH) on a Roche Elecsys 2010 analyzer using a sandwich immunoassay method (Roche 
Diagnostics), and serum fibroblast growth factor 23 (FGF-23) on a two site enzyme-linked 
immunosorbent assay (Kainos Laboratories, Inc., Tokyo, Japan). Cystatin C was measured 
in 2012-2013 using the Gentian cystatin C assay on the Roche Modular P Chemistry 
analyzer, and serum creatinine in 1990-1992 using a modified kinetic Jaffé reaction. 
Estimated glomerular filtration rate (eGFR) was calculated using the 2012 CKD EPI 
equation, which incorporates both cystatin C and creatinine(19). eGFR was categorized 
according to established clinical cut-points: ≥90, 60-89, and ≤59 ml/min/1.73 m2.
Prevalent HF was defined for exclusion by any of the following: an affirmative response to 
“Were any of the medications you took during the last 2 weeks for heart failure?”, Stage 3 or 
“manifest heart failure” by Gothenburg criteria(20,21), or incident HF hospitalization 
between visits 1 and 2. Pre-existing CHD was defined by self-reported prior physician 
diagnosis of myocardial infarction (MI) or coronary revascularization, prevalent MI by 12 
lead ECG at visit 1, or an incident adjudicated CHD event between visits 1 and 2. Incident 
CHD was used as a time-varying covariate, and defined as the first occurrence of a validated 
definite or probable hospitalized MI or a definite CHD death.
Vitamin D Binding Protein SNPs
SNP genotypes for rs7041 and rs4588 were obtained from the ITMAT-Broad-CARe Chip, a 
custom 50K SNP genotyping array, with genotyping performed at the Broad Institute of the 
Massachusetts Institute of Technology and Harvard. Quality control procedures have been 
previously published(22).
Outcome Ascertainment
Hospitalizations and deaths through December 31, 2010 were identified through 1) annual 
telephone calls to ARIC cohort participants (or proxy), 2) active surveillance of local 
hospital discharge indexes, 3) searching state death records, and 4) linkage to the National 
Death Index. HF incidence was defined as the first occurrence of either a hospitalization that 
included an International Classification of Diseases, 9th Revision (ICD-9) discharge code of 
428 (428.0 to 428.9) among the primary or secondary diagnoses or else a death certificate 
with an ICD-9 code of 428 or an ICD-10 code of I50 among any of the listed diagnoses or 
underlying causes of death(21).
Statistical analysis
Visit 2 serum 25(OH)D was calculated as the sum of 25(OH)D2 and 25(OH)D3. We 
accounted for seasonal variation in 25(OH)D levels by computing the residuals from a linear 
regression model with 25(OH)D as the dependent variable and month of blood draw 
(modeled categorically) as the independent variable. By definition, these residuals are 
uncorrelated with month of blood draw. The grand mean was then added to the 25(OH)D 
residuals obtained from this model. This adjustment was performed separately for whites 
and for blacks, as seasonal variation in 25(OH)D also differs by race. This new variable 
“25(OH)D adjusted for month of blood draw” is an estimate of average annual 25(OH)D 
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levels and was used as the exposure variable in all analyses. Secondarily we also explored 
associations of the vitamin D epimer [3-epi-25(OH)D3] with risk of incident HF.
Characteristics of participants at visit 2 are reported separately for blacks and whites, 
stratified by quintile of 25(OH)D. For the primary analysis, Cox proportional hazards 
regression was used to determine associations between 25(OH)D and incident HF. Person-
time accrued from the date of the participants’ visit 2 exam until incident HF, loss-to-follow-
up, death, or December 31, 2010, whichever came first. Restricted cubic splines were used 
to explore the dose-response association. We tested the linear trend across the 25(OH)D 
quintiles by modeling the median of each quintile as a linear term, and separately tested the 
HR per 1 standard deviation (SD; 8.53 ng/mL) increment of 25(OH)D. Our first model 
adjusted for demographics. Model 2 additionally adjusted for educational attainment, 
physical activity, smoking status and BMI. Model 3 further adjusted for traditional 
cardiovascular risk factors (see table footnote). In additional models, we also adjusted, 
separately, for eGFR categories, serum magnesium, PTH, FGF-23, serum albumin, and 
incident CHD, the latter as a time-varying covariate. Cross-product terms were included in 
the models to evaluate interactions; stratified results are reported, as appropriate. For SNPs, 
an additive genetic model was employed. In sensitivity analyses, we restricted our analysis 
to participants whose self-reported health was good or excellent at visit 2. The proportional 
hazards assumption was evaluated quantitatively by testing the interaction between 
25(OH)D quintiles and ln(time), and qualitatively by inspection of ln(-ln) survival curves. 
SAS version 9.2 was used.
Results
The analytic sample of 12,215 participants was on average 57 years old, 24% were black, 
56% female, 34% had prevalent HTN and 5% prevalent CHD. Race-stratified associations 
between serum 25(OH)D levels and potential covariates are presented in Table 1 (quintiles 
1, 3, and 5 only) and in Supplemental Table 1 (all quintiles). Median 25(OH)D was 25.6 
ng/mL in whites, and 18.2 ng/mL in blacks. In both racial groups participants with low 
vitamin D tended to be younger, female, less active, more overweight, more likely to have 
diabetes, and have higher hsCRP and PTH. Among whites, low 25(OH)D was also 
associated with more adverse blood pressure and lipid profiles.
Race, 25(OH)D, and incident HF
Over a median follow-up of 18 years (max 21), a total of 1,799 incident HF events accrued 
(1,252 among whites, 547 among blacks). The association between 25(OH)D and incident 
HF varied by race (model 1, pinteraction = 0.02) as visually depicted by the restricted cubic 
spline models (Figures 1A and 1B) and shown in Table 2. As shown in Figure 1A, among 
whites there appeared to be a threshold effect whereby HF risk was increased at 25(OH)D 
levels below 20 ng/mL, but at levels above 20 ng/mL risk was constant. In multivariable 
analyses (Table 2) whites in the lowest quintile of 25(OH)D were at 1.98 (95% CI: 1.65, 
2.38) times greater risk of incident HF, after accounting for age and sex. Further adjustment 
for behaviors and BMI attenuated the HR to 1.42 (1.17, 1.72), while with additional 
adjustment for numerous cardiovascular risk factors that may be on the causal pathway 
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between 25(OH)D and HF the HR was 1.27 (1.04, 1.55). Estimates were similar with further 
adjustment for eGFR category, PTH, FGF23, serum albumin, serum magnesium, prevalent 
CHD, and incident MI as a time-varying covariate (data not shown). Results were also 
similar in sensitivity analyses which restricted the sample to participants who self-reported 
being in good or excellent health at visit 2 [n total/HF events = 10,316/1,276): Model 1 
HR(Q1 vs. Q5) 1.85 (1.49, 2.29); p-trend <0.0001].
Among blacks, regardless of the degree of adjustment, there was no evidence of an 
association between 25(OH)D and incident HF (Table 2, Figure 1B).
There was no evidence of interaction in the association of 25(OH)D with incident HF by 
age, sex, serum magnesium, prevalent hypertension or prevalent CHD in either blacks or 
whites (pinteraction >0.05 for all). In sensitivity analyses when race-specific quintiles were 
employed, a similar pattern was observed (data not shown). There was also no evidence that 
the 3-epi-25(OH)D3 epimer was associated with HF risk, after accounting for 25(OH)D in 
either the full population (Supplemental Table 2), or race-stratified analyses. The 3-
epi-25(OH)D3 and 25(OH)D are correlated at r = 0.46.
DBP gene polymorphisms, 25(OH)D, and incident HF
Frequencies of key DBP gene polymorphisms varied by race. Among whites for rs7041 the 
G allele frequency was 56%, while in blacks it was 16%. For rs4588 the A allele frequency 
was 28% in whites and 10% in blacks.
DBP gene polymorphism rs7041 modified the association between 25(OH)D and incident 
HF in the full ARIC sample (pinteraction = 0.001 across all models), even after adjusting for 
race. Stratified results are presented in Table 3, Figure 2, and Supplemental Table 3; note 
different referent categories for Table 3 and Fig 2. Among those with the GG allele, who 
would be genetically predisposed to higher DBP levels, the HR for those in the lowest 
versus highest quintile of 25(OH)D was 2.53 (1.80, 3.55) after demographic adjustments. 
For those who were GT for rs7041 the HR for extreme 25(OH)D quintiles was 1.63 (1.27, 
2.08), while among those who were TT the HR was 1.18 (0.85, 1.64). With additional 
adjustment for behaviors and cardiovascular risk factors, the association among those who 
were GG remained statistically significant [1.67 (1.15, 2.42)] but was null for those with the 
TG and TT alleles.
In race stratified analyses (Table 3 and Supplemental Table 3), there was suggestive 
evidence that rs7041 modified the association between 25(OH)D and HF in both whites and 
blacks: whites pinteraction Model 1 = 0.01, Model 2 = 0.01, Model 3 = 0.01; blacks pinteraction 
Model 1 = 0.03, Model 2 = 0.02, Model 3 = 0.01. In whites, similar to the full ARIC 
population, associations were strongest among participants who were GG. Due to the low G 
allele frequency among blacks we combined the GG and TG categories. The association 
between 25(OH)D and incident HF was stronger among those with either GG or TG alleles, 
relative to those with the TT allele.
There was no evidence that rs4588 modified the association between 25(OH)D and incident 
HF (data not shown; pinteraction >0.5 in all models).
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In this large community-based sample of 9,311 white and 2,904 black participants of the 
ARIC Study we found important variation in the association between 25(OH)D and HF risk 
by both race and key DBP gene polymorphisms. Low 25(OH)D was associated with greater 
HF risk among whites, even after accounting for numerous potential mediators, suggesting 
that low 25(OH)D may influence HF risk independent of these established cardiovascular 
risk factors. 25(OH)D was unrelated to HF risk in blacks. Furthermore, we provide evidence 
suggesting that, in both racial groups, presence of the rs7041 G allele may be synergistic 
with low 25(OH)D in increasing HF risk. This allele is less common in blacks, thus 
predisposing blacks to lower DBP levels and more bioavailable vitamin D relative to whites. 
Hence, variation in DBP may underlie the race interaction observed between 25(OH)D 
concentrations and HF risk.
These findings extend the results of prior studies in that 1) very little research has evaluated 
the prospective association between 25(OH)D and incident HF, 2) studies of 25(OH)D and 
cardiovascular risk have generally included relatively few events among blacks – a pertinent 
group given that they have both low levels of 25(OH)D and are at greatest risk of HF, and 3) 
by exposing an interaction between DBP SNPs and 25(OH)D on HF risk, which may partly 
explain racial variation in the association between 25(OH)D and HF.
25(OH)D, race, and incident HF
Prior knowledge about the association between 25(OH)D and HF risk is limited, particularly 
among non-whites. Among members of the Utah-based Intermountain Healthcare System 
(~86% white) those with low 25(OH)D levels (<15 vs. >30 ng/mL) were at 2-fold greater 
risk of incident HF or HF mortality, after adjusting for potential mediators(8). Similarly, in a 
prospective analysis of Germans (100% white) referred for coronary angiography, those 
with 25(OH)D <10 ng/mL vs. >30 ng/mL were at 2.8-fold greater HF risk, after accounting 
for potential mediators(9). Low 25(OH)D has also been linked to HF in cross-sectional data 
from NHANES(23), and is common among HF patients (24,25). However vitamin D 
supplementation did not improve physical performance in a recent clinical trial of heart 
failure patients(26).
Our findings in whites – that low 25(OH)D is associated with greater risk of incident HF 
independent of traditional cardiovascular risk factors – are consistent with results from the 
prior prospective studies. However, the ARIC population differs in that it was community-
based, whereas the Intermountain population consisted of people in whom 25(OH)D levels 
were drawn for clinical indications (e.g. osteoporosis risk)(8), and in the German population 
over 65% had prevalent CHD(9). People with comorbidities may have lower sunlight 
exposure as they may be less likely to participate in outdoor recreational activities, and thus 
have lower 25(OH)D levels. In ARIC our findings were robust even when the analysis was 
restricted to those self-reporting good or excellent health.
There are no prior studies of 25(OH)D and HF incidence in blacks with which to compare 
our findings. However, similar race interactions between 25(OH)D and incidence of other 
CVD outcomes have been reported(13,14).
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DBP gene polymorphisms, 25(OH)D, and incident HF
Racial variation in the DBP SNP rs7041 may be an important contributor to the race 
interaction we observed between 25(OH)D and HF risk. Frequency of the G allele varies 
dramatically by race (56% in whites, and 16% in blacks in ARIC, which is similar to other 
studies(15)). Each copy of this allele is associated approximately 189 ug/mL higher levels of 
DBP(15), which should result in lower levels of bioavailable vitamin D. As recently shown 
by Powe et al(15), blacks have lower DBP levels and lower 25(OH)D concentrations 
compared to whites, resulting in similar levels of bioavailable vitamin D. Approximately 
85-90% of circulating 25(OH)D is tightly bound to vitamin D binding protein and therefore 
is generally believed to be unavailable for use. The remaining circulating 25(OH)D (of 
which 10-15% is bound to albumin and <1% free) is considered bioavailable.
Our finding that associations between low 25(OH)D and incident HF were stronger among 
participants who were GG for rs7041 (HR: 2.53) relative to those who were GT (1.63) or TT 
(1.18) suggests that HF risk at a given concentration of 25(OH)D may be greater in those 
genetically predisposed to have higher DBP, and likely subsequently lower bioavailable 
vitamin D. Importantly, there was evidence of this interaction among both blacks and 
whites.
We did not observe an interaction between rs4588 and 25(OH)D on risk of incident HF. 
However power was lower as the rs4588 A allele frequency is only 28% in whites and 10% 
in blacks, and each copy of the A allele is associated with a more modest increase in levels 
of DBP (~55 ug/mL), relative to each copy of the rs7041 G allele (~189 ug/mL)(15).
To our knowledge, no other study has assessed whether DBP SNPs modify the association 
between 25(OH)D and cardiovascular risk. One prior study evaluated the main effect 
between DBP SNPs and stroke risk, but found no association (27).
Strengths and limitations
The most prominent strength of this investigation is the large community-based sample of 
black and white adults. Nearly 1,800 incident HF events accrued (over 500 among blacks), 
therefore allowing us reasonable power to evaluate interactions and perform key subgroup 
analyses. Also, the ARIC population is well characterized, allowing adjustment for 
numerous potential confounders and mediators. The most important limitations of this work 
are its observational nature, and the fact that DBP concentrations were not available; 
therefore, we were unable to calculate bioavailable vitamin D. Also, 25(OH)D was only 
measured once, and thus regression dilution bias may have attenuated relative hazard 
estimates(28). Though not possible for this manuscript given ARIC’s design, it has been 
recommended that prospective cohort studies measure serum 25(OH)D concentrations every 
2-4 years in order to obtain more accurate estimates of associations between 25(OH)D and 
outcomes(29). Lastly, HF events were identified through ICD codes from hospital discharge 
and death certificates, and thus cases of HF which were managed exclusively in outpatient 
settings would have been missed. However, ARIC has shown HF ICD codes to have high 
validity(30).
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In this prospective community-based cohort low 25(OH)D concentrations (particularly <20 
ng/mL) were associated with greater risk of incident HF among whites, independent of 
traditional cardiovascular risk factors thought to mediate the association. Among blacks, 
there was no evidence of a relation. Our results also suggest that, regardless of race, low 
25(OH)D was a more potent risk factor among individuals genetically predisposed to high 
DBP levels, and by extension lower bioavailable vitamin D. These findings provide novel 
insight into metabolic differences that may underlie racial variation in the association 
between 25(OH)D and cardiovascular risk. Vitamin D supplementation is not presently 
recommended for cardiovascular disease prevention(4); our results suggest that were it 
recommended, a “one dose fits all” approach may be inappropriate. Supplementation, if 
recommended, would likely only benefit those who are deficient, and levels of bioavailable 
D may need to be taken into account.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Association of serum 25(OH)D with risk of incident HF: The ARIC Study 1990-2010.
Biomarkers modeled as restricted cubic splines with knots at the 5th, 27.5th, 50th, 72.5th and 
95th percentiles, and are adjusted for age and sex.
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Adjusted* hazard ratios (95% confidence intervals) of baseline serum 25(OH)D with 
incident heart failure stratified by rs7041, the ARIC Study 1990-2010.
* Adjusted for age, sex, and race. Participants with the GG genotype and the highest quintile 
of vitamin D are the reference for all comparisons. P-interaction = 0.01 for rs7401 and 
25(OH)D quintiles on HF risk.
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